46
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Carcinoma en cuirasse caused by pleomorphic lobular carcinoma of the breast in a man

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction Breast carcinoma, the most common malignancy in women, is rarely diagnosed in men. Approximately 1,910 new cases of breast carcinoma in men are reported annually 1 compared with more than 230,000 new cases in women. 2 Most male cases (90%) are of the invasive ductal subtype. 3 The lifetime risk of breast cancer for men in the general population is 0.1%. 1 Genetic predisposition significantly heightens this risk, with mutations in BRCA2 increasing the lifetime risk to an estimated 5% to 10%. 1 Inactivation of other tumor suppressors, including BRCA1, PTEN, p53, and CHEK2, is also found to confer an increased risk in men.1, 3 Congenital disorders such as Klinefelter's syndrome contribute to at least 3% of the incidence of all male breast cancer. 1 We report a 77-year-old man presenting with a painful right axillary mass diagnosed as metastatic carcinoma of unknown primary. Despite multiple treatment modalities, his disease progressed to the brain, lungs, and skin as carcinoma en cuirasse. Histopathologic diagnosis at autopsy was pleomorphic lobular carcinoma (PLC), an uncommon subtype of breast cancer that is reported rarely in men. Case report A 77-year-old man with a 50-pack-year smoking history presented to our institution with an enlarging, painful, right axillary mass. Fine-needle aspiration and excisional biopsy were consistent with metastatic carcinoma of unknown primary. Histology testing found infiltrates of tumor nodules with large, pleomorphic, poorly differentiated epithelial cells extending into the surrounding fibrofatty tissue and lymphatics. Immunohistochemical stains were positive for cytokeratin 7 and epithelial-membrane antigen but negative for lymphocytic markers (CD3, CD20, CD45), caudal type homeobox gene 2 (CTH2), prostate-specific antigen (PSA), progesterone receptor (PR), estrogen receptor (ER), and thyroid transcription factor 1 (TTF1). Computed tomography (CT) scan of the chest found right axillary and subpectoral adenopathy (Fig 1). Positron emission tomography/CT scan found fluorodeoxyglucose uptake in the right neck and chest consistent with a neoplastic process. The patient received multiple treatment modalities, complicated by intermittent periods of poor follow-up. Therapy included 5 cycles of carboplatin and paclitaxel, 1 cycle of docetaxel, and palliative radiotherapy. Fourteen months after initiating treatment, a workup for dyspnea found malignant effusion and brain metastases. The patient was referred to hospice care; however, 3 months later, he presented with worsening dyspnea. At this time, the right anterior chest wall and neck were encased in an erythematous, sclerotic plaque, composed of approximately 0.5- to 1.0-cm firm papules, sparing the nipples (Fig 2, A). The affected skin showed a peau d'orange appearance with peripheral papulonodules and pseudovesicular papules (Fig 2, B). The ipsilateral arm was exquisitely tender with 4 + pitting edema. CT scan found complete collapse of the right lung with massive pleural effusion; irregular, nodular, soft-tissue densities were seen on the right anterior chest wall, suspected to be the primary source. On brain magnetic resonance imaging, metastases had enlarged and several new enhancing lesions were noted. Skin biopsy found epidermal spongiosis with interstitial fibrosis and thickened collagen bundles in the dermis. Atypical cells infiltrating in a single file pattern and abundant mucin deposition were found (Fig 3). Immunohistochemistry was positive for cytokeratin 7, and negative for cytokeratin 20, TTF1, PSA, and CTH2, consistent with carcinoma. Shortly thereafter, he died of a septic episode. At autopsy, the pericardial sac and pleura were studded with white, firm nodules, and the skin showed metastatic carcinoma. Immunohistochemistry was positive for pan cytokeratin, gross cystic disease fluid protein 15, and mammaglobin and negative for E-cadherin, ER, PR, and HER2/neu. The final pathologic diagnosis was pleomorphic lobular carcinoma of the breast, apocrine subtype, with metastases to skin, brain, lungs, pleura, pericardium, diaphragm, chest wall muscle, and lymph nodes. Discussion Invasive lobular carcinoma of the male breast is rare, owing to the absence of lobules and acini in male breast tissue, representing only 1% of male breast cancer. 3 PLC is an uncommon highly aggressive subtype, with few reported cases in men. 4 PLC often presents at an advanced stage, is likely to be larger with more positive lymph nodes at time of diagnosis, and carries an increased risk of lymphovascular invasion and distant metastases. 5 Cytologically, it is characterized by enlarged nuclei, prominent nucleoli, increased hyperchromasia, frequent mitotic figures, and eosinophilic cytoplasm.5, 6 Histologically, PLC shows loss of E-cadherin expression and no expression of ER and PR and has a high rate of HER2/neu gene amplification. 6 However, HER2 gene amplification appears to be variable in male PLC cases. 4 In this patient, the apocrine subtype was suspected, associated with significantly more genomic alterations than the nonapocrine type. 6 Breast cancer is a common malignancy to metastasize to the skin. Carcinoma en cuirasse, a distinct clinicopathologic type of cutaneous metastasis, was coined by Velpeau in 1838 to describe a thick, leathery breast plate of cancer involving the chest and abdominal wall. 7 Primary carcinoma en cuirasse is rare, presenting as extensive skin involvement in the setting of untreated malignancy; secondary disease is more common, presenting as a local chest wall recurrence after mastectomy, radiation, or chemotherapy. 8 In this case, carcinoma en cuirasse was caused by occult breast cancer. The pathogenesis of carcinoma en cuirasse remains largely unknown. It is speculated that pleiotrophin, an extracellular signaling molecule, acts as a multifunctional tumor promoter leading to rapid tumor growth and progression to the scirrhous subtype of invasive carcinoma. 9  Clinically, this carcinoma begins as scattered, firm, papulonodules overlying an erythematous skin surface progressing to brawny hardness, which eventually coalesces into a sclerodermoid plaque.7, 8 Histologically, there is extensive dermal fibrosis with single filing of atypical malignant cells; tumors cells may be overlooked because of similarity in appearance to fibroblasts. 10 Treatment options are limited. Because the tumor cells cause extensive reactive fibrosis and decreased vascularity, chemotherapeutic agents may be unable to obtain tumoricidal concentrations locally.8, 10 The goal is palliative; local irradiation, skin graft, and nonsteroidal anti-inflammatory drug therapy have shown some success. To our knowledge, this is the first reported case of carcinoma en cuirasse caused by male breast cancer, and the fifth reported case of PLC in a man. Our case serves to highlight the rapid progression of this rare malignancy and the challenges associated with early detection, diagnosis, and treatment.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: not found

          Male breast cancer.

          Occurrence of male breast cancer, a rare disease, peaks at age 71 years. Familial cases usually have BRCA2 rather than BRCA1 mutations. Occupational risks include high temperature environments and exhaust fumes, but electromagnetic fields have not been implicated. Hyperoestrogenisation resulting from Klinefelter's, gonadal dysfunction, obesity, or excess alcohol, all increase risk as does exposure to radiation, whereas gynaecomastia does not. Presentation is usually a lump or nipple inversion, but is often late, with more than 40% of individuals having stage III or IV disease. Most tumours are ductal and 10% are ductal carcinoma in situ. Surgery is usually mastectomy with axillary clearance or sentinel node biopsy. Indications for radiotherapy, by stage, are similar to female breast cancer. Because 90% of tumours are oestrogen-receptor-positive, tamoxifen is standard adjuvant therapy, but some individuals could also benefit from chemotherapy. Hormonal therapy is the main treatment for metastatic disease, but chemotherapy can also provide palliation. National initiatives are increasingly needed to improve information and support for male breast cancer patients.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Multidisciplinary meeting on male breast cancer: summary and research recommendations.

            Male breast cancer is a rare disease, accounting for less than 1% of all breast cancer diagnoses worldwide. Most data on male breast cancer comes from small single-institution studies, and because of the paucity of data, the optimal treatment for male breast cancer is not known. This article summarizes a multidisciplinary international meeting on male breast cancer, sponsored by the National Institutes of Health Office of Rare Diseases and the National Cancer Institute Divisions of Cancer Epidemiology and Genetics and Cancer Treatment and Diagnosis. The meeting included representatives from the fields of epidemiology, genetics, pathology and molecular biology, health services research, and clinical oncology and the advocacy community, with a comprehensive review of the data. Presentations focused on highlighting differences and similarities between breast cancer in males and females. To enhance our understanding of male breast cancer, international consortia are necessary. Therefore, the Breast International Group and North American Breast Cancer Group have joined efforts to develop an International Male Breast Cancer Program and to pool epidemiologic data, clinical information, and tumor specimens. This international collaboration will also facilitate the future planning of clinical trials that can address essential questions in the treatment of male breast cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cutaneous metastatic disease.

              The relative frequencies of cutaneous metastases are similar to those of the primary cancers; breast, colon, and melanoma are the most frequent in women and lung, colon, and melanoma are the most common in men. Cutaneous metastases represent an opportunity to detect a potentially treatable cancer before other evidence of it is present, to modify therapy as appropriate to the tumor stage, or possibly to use the cutaneous lesion as a source of easily accessible tumor cells for specific therapy. Cutaneous metastatic disease as the first sign of internal cancer is most commonly seen with cancer of the lung, kidney, and ovary.
                Bookmark

                Author and article information

                Contributors
                Journal
                JAAD Case Rep
                JAAD Case Rep
                JAAD Case Reports
                Elsevier
                2352-5126
                13 August 2016
                July 2016
                13 August 2016
                : 2
                : 4
                : 317-319
                Affiliations
                [a ]Department of Dermatology, College of Physicians and Surgeons, Columbia University, New York, New York
                [b ]Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, New York
                [e ]Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, New York
                [c ]Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts
                [d ]Path Logic, West Sacramento, California
                Author notes
                []Correspondence to: Christine T. Lauren, MD, Department of Dermatology, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Avenue, 12 th floor, New York, New York.Department of DermatologyColumbia University Medical CenterHerbert Irving Pavilion161 Fort Washington Avenue12 th floorNew YorkNew York cat35@ 123456cumc.columbia.edu
                Article
                S2352-5126(16)30056-X
                10.1016/j.jdcr.2016.06.006
                4987509
                27556062
                bcaa78c5-984f-446b-8053-f2ed302b743b
                © 2016 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                Categories
                Case Report

                breast cancer,carcinoma en cuirasse,carcinoma of unknown primary,cutaneous metastasis,metastatic carcinoma,pleomorphic lobular carcinoma,radiation therapy,cth2, caudal type homeobox gene 2,er, estrogen receptor,plc, pleomorphic lobular carcinoma,pr, progesterone receptor,psa, prostate-specific antigen,ttf1, thyroid transcription factor 1

                Comments

                Comment on this article